|

RD13-02 cell infusion Clinical Trials

1 actively recruiting trial

Also known as: universal CD7 CAR-T cells

Pipeline

Phase 1: 1

Top Sponsors

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1

Indications

  • CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies1
  • NK/T-cell Lymphoma1
  • CART Therapy1
  • Cancer1

Other1 trial

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.